SCHEMBL2352345

SCHEMBL2352345

CCCCCCCCC(C)C([O])(CC)CC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 3/20 0.43
FFAR1 O14842 1/20 0.43
OPRM1 P35372 1/20 0.41
ADH1B P00325 1/20 0.41
ADH1C P00326 1/20 0.41
ADH1A P07327 1/20 0.41
ADH4 P08319 1/20 0.41
ADH7 P40394 1/20 0.41
ACE2 Q9BYF1 1/20 0.39
FDPS P14324 4/20 0.39
CA1 P00915 2/20 0.39
SPHK1 Q9NYA1 1/20 0.39
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
TP53 P04637 1/20 0.38
LCK P06239 1/20 0.38
PPARD Q03181 1/20 0.38
ZDHHC20 Q5W0Z9 1/20 0.38
ZDHHC2 Q9UIJ5 1/20 0.38
DNM1 Q05193 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2350108 0.91 TSHR (0.39) GPR84FFAR1OPRM1FDPSCA1
SCHEMBL2348714 0.90 GGPS1 (0.39) GPR84FFAR1OPRM1ADH1BADH1C
SCHEMBL2346562 0.84 ADH1B (0.39) GPR84FFAR1OPRM1ADH1BADH1C
SCHEMBL2348900 0.84 ADH1B (0.39) GPR84FFAR1OPRM1ADH1BADH1C
SCHEMBL2344959 0.84 GGPS1 (0.42) GPR84FFAR1OPRM1ADH1BADH1C
SCHEMBL2350127 0.83 GGPS1 (0.41) GPR84FFAR1OPRM1ADH1BADH1C
SCHEMBL2346700 0.81 GGPS1 (0.39) GPR84FFAR1OPRM1ADH1BADH1C
SCHEMBL2347905 0.80 TSHR (0.35) OPRM1FDPSDNM1
SCHEMBL6328353 0.79 OPRM1 (0.42) GPR84FFAR1OPRM1ADH1BADH1C
SCHEMBL7892718 0.79 OPRM1 (0.42) GPR84FFAR1OPRM1ADH1BADH1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2078724-B1 PROCESS FOR PRODUCTION OF DIALKYLTIN DIALKOXIDES ASAHI CHEMICAL IND (JP) 2016-11-30 EP disclosed
EP-2226328-B1 PROCESS FOR PRODUCTION OF ALKYL TIN ALKOXIDE COMPOUND, AND PROCESS FOR PRODUCTION OF CARBONATE ESTER USING THE COMPOUND ASAHI KASEI CHEMICALS CORP (JP) 2012-12-26 EP disclosed
US-8168812-B2 Process for producing alkyl tin alkoxide compound and process for producing carbonic acid ester using said compound ASAHI KASEI CHEMICALS CORPORATION (JP) 2012-05-01 US disclosed
US-8008518-B2 Process for producing dialkyl tin dialkoxides ASAHI KASEI CHEMICALS CORPORATION (JP) 2011-08-30 US disclosed
US-20100292496-A1 Process for Production of Alkyl Tin Alkoxide Compound, and Process for Production of Carbonic Acid Ester Using the Compound ASAHI KASEI KABUSHIKI KAISHA (JP) 2010-11-18 US disclosed
EP-2226328-A1 PROCESS FOR PRODUCTION OF ALKYL TIN ALKOXIDE COMPOUND, AND PROCESS FOR PRODUCTION OF CARBONATE ESTER USING THE COMPOUND Asahi Kasei Chemicals Corporation (JP) 2010-09-08 EP disclosed
US-20100041908-A1 PROCESS FOR PRODUCING DIALKYL TIN DIALKOXIDES ASAHI KASEI KABUSHIKI KAISHA (JP) 2010-02-18 US disclosed
EP-2078724-A1 PROCESS FOR PRODUCTION OF DIALKYLTIN DIALKOXIDES Asahi Kasei Chemicals Corporation (JP) 2009-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041908-A1 PROCESS FOR PRODUCING DIALKYL TIN DIALKOXIDES DEK, DDT, DERA GPR84 3869/4885FFAR1 2261/4885OPRM1 4657/4885
US-20100292496-A1 Process for Production of Alkyl Tin Alkoxide Compound, and Process for Production of Carbonic Acid Ester Using the Compound OXSR1, AOC2, OXER1 GPR84 1093/4885FFAR1 1034/4885OPRM1 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.